Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Sana Biotechnology

Main focus: Cellular engineering for genetic diseases and cancer

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR-Cas12b

Funding stage: Public (NASDAQ:SANA)

Location: Seattle, Washington, United States



Partners: Beam Therapeutics

Sana Biotechnology is a Seattle-based company that focuses on the development of in vivo and ex vivo engineered cell therapies. Using its Fusogen technology platform, the company aims to create in vivo engineered CAR-T cells, which might circumvent many of the obstacles associated with conventional CAR-T cell therapies. Likewise, the company's Hypoimmune technology is being applied for the development of ex vivo engineered donor- and stem cell-derived cellular therapies. The company has obtained licenses from Beam Therapeutics to use the CRISPR-Cas12b system as part of a number of its ex vivo engineered cell programmes.


HashtagSana Biotechnology

Company: Sana Biotechnology
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine